ArticleJTCVS open2025
Accuracy of DOTATATE-positron emission tomography for preoperative nodal staging of carcinoid tumors of the lung.
Article in JTCVS open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Toward Precision Imaging in Lung NET: A Clinically Oriented Framework Integrating Dual Tracer PET and Radiomics.Cancers · 2026Review
- National analysis of the incidence and prognostic importance of nodal metastases in atypical lung carcinoid tumors.JTCVS open · 2026Article
- European Society of Neuroendocrine Tumors (ENETS) 2025 guidance paper for lung and thymic carcinoids.Journal of neuroendocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: DOTATATE-positron emission tomography (PET) scans use a radiotracer that binds somatostatin receptor 2 on neuroendocrine cells to identify carcinoid tumors. Use of DOTATATE-PET during preoperative evaluation of lung carcinoids is increasing, but the accuracy of DOTATATE-PET in nodal staging of pulmonary carcinoids is unknown. Methods: We reviewed patients with lung carcinoids undergoing DOTATATE-PET before surgical resection between November 2013 and 2023. Exclusions included non-avid primary tumors on DOTATATE-PET or absent pathologic lymph node assessment. Using surgical pathology as the gold standard, we assessed concordance between DOTATATE-PET-based clinical stage and postoperative pathologic stage. Sensitivity, specificity, negative predictive value, and positive predictive value were calculated, with χ Results: Among 58 patients undergoing resection of lung carcinoid tumors (48 typical, 10 atypical carcinoids), 15 (25.8%) had pathologic nodal involvement, but DOTATATE-PET detected only 3. For the 43 patients who were pathologic node-negative, DOTATATE-PET was negative in 42. This yielded 42 true negatives, 3 true positives, 12 false negatives, and 1 false positive, with sensitivity of 20%, specificity 97.7%, negative predictive value 77.8%, positive predictive value 75%, and overall accuracy of 77.6%. Larger tumor size was significantly associated with inaccurate DOTATATE-PET ( Conclusions: DOTATATE-PET has poor sensitivity for nodal disease in patients with pulmonary carcinoid tumors. Thorough pathologic lymph node evaluation is necessary regardless of DOTATATE-PET results when resecting carcinoid tumors. Given that primary surgery is indicated even if it were known there were positive lymph nodes, the utility of a DOTATATE-PET is likely limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.